You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

GVHD.

Showing 26 - 50 of 2,346
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Intestinal GVHD, Steroid Refractory GVHD Trial in France (Blood and stool sample collection)

Recruiting
  • Intestinal GVHD
  • Steroid Refractory GVHD
  • Blood and stool sample collection
  • Amiens, France
  • +8 more
Jun 20, 2022

Chronic GVHD Response Measures Validation

Active, not recruiting
  • Graft vs Host Disease
    • Seattle, Washington
      Fred Hutchinson Cancer Research Center
    Feb 28, 2022

    Acute Leukemia, MDS, Myeloproliferative Tumor Trial in Minneapolis (VIC- 1911)

    Recruiting
    • Acute Leukemia
    • +3 more
    • VIC- 1911
    • Minneapolis, Minnesota
      Masonic Cancer Center at University of Minnesota
    Apr 12, 2022

    Acute GVHD Trial (MTX, Corticosteroid)

    Not yet recruiting
    • Acute Graft Versus Host Disease
    • (no location specified)
    Jun 26, 2023

    Cytomegalovirus Infection After HSCT and PT-CY as GVHD

    Completed
    • CMV Infection
      • Malaga, Spain
        Maria Jesus Pascual
      Mar 30, 2022

      Graft Vs Host Disease Trial in Vandoeuvre Les Nancy (Uvadex, Steroids)

      Not yet recruiting
      • Graft Vs Host Disease
      • Vandoeuvre Les Nancy, France
        CHRU de Nancy
      Nov 10, 2023

      GVHD, Postbiotics, Butyrate Trial in Seoul (sodium butyrate)

      Recruiting
      • Graft Versus Host Disease
      • +2 more
      • sodium butyrate
      • Seoul, Korea, Republic of
        Soonchunhyang University Seoul Hospital
      Apr 11, 2023

      GVHD Trial in Shenzhen, Shanghai (PTCY)

      Not yet recruiting
      • GVHD
      • Shenzhen, GaungDong, China
      • +1 more
      Aug 17, 2023

      GVHD, Acute Stem Cell Transplant Complications Trial in Chendu (Ruxolitinib)

      Not yet recruiting
      • GVHD
      • Acute Stem Cell Transplant Complications
      • Chendu, Sichuan, China
        West China Hospital, Sichuan University
      Oct 3, 2023

      Evaluation of GvHD Damage on Medullary Mesenchymal Stem Cells

      Recruiting
      • Graft Vs Host Disease
      • no intervention
      • Torino, Italy
        AOU Città della Salute e della Scienza di Torino
      Dec 7, 2021

      GVHD Trial in Ramat Gan (Cyclophosphamide, anti-human T-lymphocyte immunoglobulin (ATLG))

      Recruiting
      • Graft Versus Host Disease
      • Ramat Gan, Israel
        Chaim Sheba Medical Center
      May 4, 2022

      Hematologic Malignancy, Myeloid Malignancy Trial in Memphis (Ruxolitinib, Mesna, Anti-thymocyte globulin (ATG))

      Recruiting
      • Hematologic Malignancy
      • Myeloid Malignancy
      • Memphis, Tennessee
        St. Jude Children's Research Hospital
      Nov 7, 2022

      Steroid Refractory GVHD Trial in Taoyuan (Ruxolitinib)

      Completed
      • Steroid Refractory GVHD
      • Taoyuan, Taiwan
        Chang Gung Memorial Hospital
      Dec 15, 2022

      Aplastic Anemia Trial in Suzhou (CD20 mAb, ATG)

      Recruiting
      • Aplastic Anemia
      • CD20 monoclonal antibody
      • ATG
      • Suzhou, Jiangsu, China
        The First Affiliated Hospital of Soochow University
      Aug 21, 2022

      Acute Graft Versus Host Disease

      Not yet recruiting
      • GVHD,Acute
      • blood sample
      • Detroit, Michigan
        Henry Ford Health System
      Jan 30, 2023

      Dendritic Cells in Acute or Chronic Skin Graft Versus Host

      Recruiting
      • Acute Graft-versus-host Disease
      • +3 more
      • Skin punch biopsy
      • Peripheral blood draw
      • Saint Louis, Missouri
        Washington University School of Medicine
      May 31, 2022

      Acute GVHD, Steroid Refractory GVHD Trial in Columbus (BRD4 Inhibitor PLX51107)

      Recruiting
      • Acute Graft Versus Host Disease
      • Steroid Refractory Graft Versus Host Disease
      • BRD4 Inhibitor PLX51107
      • Columbus, Ohio
        Ohio State University Comprehensive Cancer Center
      Mar 24, 2022

      Acute Lymphoblastic Leukemia, Myeloblastic Leukemia, Biphenotypic Acute Leukemia Trial (GVHD prevention: post-transplantation

      Not yet recruiting
      • Acute Lymphoblastic Leukemia
      • +5 more
      • GVHD prevention: post-transplantation cyclophosphamide, abatacept, vedolizumab, calcineurin inhibitor
      • (no location specified)
      Aug 23, 2022

      Analysis of Intestinal Defensin Expression in Acute GVHD

      Active, not recruiting
      • GVHD,Acute
      • +2 more
        • Freiburg, Baden-Württemberg, Germany
          Medical Center University of Freiburg
        Nov 3, 2021

        Acute Leukemia, Hematologic and Lymphocytic Disorder, Myelodysplastic Syndrome Trial in Duarte (Fludarabine, Itacitinib Adipate,

        Active, not recruiting
        • Acute Leukemia
        • +4 more
        • Duarte, California
          City of Hope Medical Center
        Jan 4, 2023

        Acute Lymphoblastic Leukemia (ALL) in Partial Remission, Acute Lymphoblastic Leukemia (ALL) in Complete Remission, Acute Myeloid

        Recruiting
        • Acute Lymphoblastic Leukemia (ALL) in Partial Remission
        • +2 more
        • Riyadh, Saudi Arabia
          King Faisal Specialist Hospital & Research Center
        Apr 4, 2022

        Graft-versus-host Disease (GVHD) Trial (Ruxolitinib)

        Approved for marketing
        • Graft-versus-host Disease (GVHD)
        • (no location specified)
        Jan 26, 2023

        Chronic GVHD, Allogeneic Stem Cell Transplant Trial in Boston (App, Usual Care)

        Recruiting
        • Chronic Graft-Versus-Host Disease
        • Allogeneic Stem Cell Transplant
        • App
        • Usual Care
        • Boston, Massachusetts
          Massachusetts General Hospital Cancer Center
        Jan 24, 2023

        GVHD Trial in Durham (Prochymal®)

        Completed
        • Graft Versus Host Disease
        • Durham, North Carolina
          Duke University
        Jan 14, 2022

        Graft-versus-host Disease Trial in New York (Cyclophosphamide, Abatacept, Bortezomib)

        Recruiting
        • Graft-versus-host Disease
        • New York, New York
          NYU Langone Health
        Mar 24, 2022